Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156657 | 0.86 | RIPK1 (0.35) | — | |
| SCHEMBL2294582 | 0.80 | HDAC1 (0.30) | — | |
| SCHEMBL2298373 | 0.79 | FBP1 (0.37) | CYP1A2ALDH1A1POLB | |
| SCHEMBL21733550 | 0.74 | FFAR4 (0.36) | POLB | |
| SCHEMBL3425386 | 0.73 | RIPK1 (0.34) | — | |
| SCHEMBL1641897 | 0.73 | FBP1 (0.37) | CYP1A2ALDH1A1POLB | |
| SCHEMBL1772317 | 0.72 | RIPK1 (0.43) | MEN1KMT2A | |
| SCHEMBL1706655 | 0.71 | KEAP1 (0.47) | MEN1CYP1A2KMT2AKEAP1ALDH1A1 | |
| SCHEMBL5530171 | 0.71 | GABRA1 (0.42) | MEN1KMT2A | |
| SCHEMBL9903207 | 0.71 | POLB (0.36) | MEN1CYP1A2KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | MEN1 3602/4885CYP1A2 284/4885KMT2A 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.